Last reviewed 2026-04-20 · How we verify

Amobarbitone (AMOBARBITAL)

Amobarbital, a marketed barbiturate, competes in the epilepsy treatment market with a mechanism that enhances GABA activity to produce a calming effect. Its key strength lies in the patent protection extending until 2028, providing a period of exclusivity for its composition. The primary risk is the strong competition from off-patent generics of same-class drugs such as pentobarbital and secobarbital, which may limit market share and revenue potential.

At a glance

Approved indications

• Epilepsy
• General anesthesia
• Insomnia
• Local anesthesia
• Narcoanalysis
• Seizure disorder
• Severe anxiety (panic)
• Status epilepticus

Common side effects

No common side effects on file.

Drug interactions

• CYP2A6 Substrates
• anisindione
• aripiprazole
• dicoumarol
• estradiol
• ethinylestradiol
• phenprocoumon
• quetiapine
• risperidone
• warfarin

Key clinical trials

• Amobarbital and Cardiopulmonary Bypass (NA)
• Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions (PHASE4)
• Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA (PHASE1,PHASE2)
• Study on the Effect of Exercise Intervention Combined With Physical Therapy on Chronic Ankle Instability Symptoms (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Amobarbitone CI brief — competitive landscape report
• Amobarbitone updates RSS · CI watch RSS